GlassScriptPhysician profile
Elsa L Lerro
NPI 1366496770
$588.85
in general payments reported to CMS, 2019-2025
13 companies · $39.37 in 2025
The $39.37 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.25 · 2020: $134 · 2021: $111 · 2022: $43.48 · 2023: $121 · 2024: $98.71 · 2025: $39.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $259.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.45 | 2020-2024 | Jardiance |
| Abbvie INC. | $59.14 | 2023 | |
| Amgen INC. | $58.60 | 2020-2021 | |
| Lilly USA, LLC | $55.93 | 2023-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $48.16 | 2020-2021 | |
| Esperion Therapeutics, INC. | $47.21 | 2024-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $41.25 | 2019 | |
| Merck Sharp & Dohme LLC | $38.82 | 2020 | |
| Exact Sciences Corporation | $28.98 | 2024 | Cologuard Collection Kit |
| Philips North America LLC | $28.31 | 2022 | |
| Novo Nordisk INC | $19.94 | 2023 | Wegovy |
| Abbott Laboratories | $19.89 | 2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $15.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elsa Lerro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.